Alerta

C4A3-HNE and C4A4-HNE Assay

Resumen de: US20260219282A1

0000 Disclosed herein are methods of immunoassay for detecting HNE-generated fragments of the α3 chain or α4 chain of type IV collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. Also disclosed are monoclonal antibodies and assay kits for use in the methods of immunoassay.

HOXA11AS LONG NON-CODING RNA IN INFLAMMATORY BOWEL DISEASE

Resumen de: US20260218299A1

0000 Provided herein are gene replacement approaches to restore HOXA11AS in the colon for patients with IBD, e.g., UC. Further, since HOXA11os levels inversely correlate with disease severity this lncRNA can also be used as a sensitive colon specific disease relevant biomarker.

用于治疗腹泻型肠易激综合征的N-油酰乙醇胺和直肠真杆菌

Resumen de: WO2025185743A1

Use of N-oleoylethanolamide(OEA) or a microbiota OEA producer, such as Eubacterium rectale, in the preparation of medicament for the treatment of irritable bowel syndrome (IBS).

COMPOSITIONS, DEVICES, AND METHODS OF ULCERATIVE COLITIS SENSITIVITY TESTING

Resumen de: US20260210970A1

Contemplated test kits and methods for food sensitivity are based on rational-based selection of food preparations with established discriminatory p-value. Particularly preferred kits include those with a minimum number of food preparations that have an average discriminatory p-value of ≤0.07 as determined by their raw p-value or an average discriminatory p-value of ≤0.10 as determined by FDR multiplicity adjusted p-value. In further contemplated aspects, compositions and methods for food sensitivity are also stratified by gender to further enhance predictive value.

METHODS, KITS AND COMPOSITIONS FOR THE TREATMENT OF FOOD PROTEIN INDUCED ENTEROCOLITIS SYNDROME AND IRRITABLE BOWEL SYNDROME

Resumen de: US20260209366A1

This invention describes methods, kits, and compositions for treating Food Protein-Induced Enterocolitis Syndrome (FPIES) and a food-triggered endotype of IBS by modulating the IL-4/IL-13→IL-4Rα axis and/or the OX40-OX40L costimulatory pathway, with patient selection and monitoring guided by blood biomarkers (elevated OX40L on dendritic cells and/or OX40 on lymphocytes, including food antigen-stimulated assays). In case examples, IL-4Rα blockade (e.g., dupilumab) produced rapid, durable clinical remission with successful food reintroduction, accompanied by reduced dendritic-cell OX40L and modulation of circulating CRTH2+ Tc2 cells, whereas OX40L-low, non-food-trigger IBS showed no response—supporting a biomarker-defined responder population. Collectively, this invention demonstrates a precision framework in which IL-4Rα and OX40/OX40L antagonists—alone or in combination—enable diet liberalization and induce tolerance in FPIES and food-triggered IBS.

METHOD FOR EXAMINING INFLAMMATORY BOWEL DISEASE AND METHOD FOR SCREENING THERAPEUTIC AGENT

Resumen de: WO2026155051A1

The present invention provides an examination method for identifying a biomarker capable of detecting the remission phase of an inflammatory bowel disease, and assisting in the diagnosis of the inflammatory bowel disease, the monitoring of disease progression, or the determination of therapeutic effect.　Focusing attention on myeloid immune cells that play an important role in the pathogenesis of inflammatory bowel disease, the present inventors considered that young myeloid immune cells potentially increase even in the remission phase and may induce transition to the active phase by progression of the disease. The present inventors then proceeded with intensive studies thereon. As a result, the present inventors found that CD11b, CD33, and CD84-positive (CD11b+CD33+CD84+) cells, which are precursor cells of myeloid immune cells, can serve as blood markers for inflammatory bowel disease. Further investigation revealed that Membrane-Spanning 4-Domains A3 (Ms4a3)-positive (Ms4a3+) cells, and Ms4a3 and CD84-positive (Ms4a3+CD84+) cells significantly increase not only in the active phase but also in the remission phase, and are significantly greater in number in the active phase than in the remission phase.

ANTI-IL23 AND ANTI-TNFa ANTIBODIES: COMPOSITIONS AND VETERINARY USE

Resumen de: US20260209333A1

0000 Provided are various embodiments relating to caninized, felinized, or equinized antibodies that bind canine, feline, and/or equine IL23 and/or TNFα, including bispecific antibodies that bind to both IL23 and TNFα. Such antibodies can be used alone or in combination in methods to treat canine, feline, and/or equine subjects with inflammatory conditions, such as inflammatory conditions in canines and felines, such as inflammatory bowel disease (IBD), osteoarthritis, and gastroenteritis.

REVERSIBLE BACTERIAL PHSE-VARIATIONS AND USES THEREOF IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS

Resumen de: US20260209867A1

0000 The present disclosure relates to reversible phase variations in bacteria e.g., residing in a microbiome or any environment, and uses thereof in determining a physiological and/or environmental condition or state of a subject or a media and/or or habitat. The present disclosure thus provides methods and personalized therapeutic methods and kits.

AUTOMATIZED DETECTION OF INTESTINAL INFLAMMATION IN CROHN'S DISEASE USING CONVOLUTIONAL NEURAL NETWORK

Resumen de: US20260212495A1

0000 The invention relates to system and methods for predicting and/or diagnosing of IBD from ultrasound images according to one or more of diagnostic signs.

Noninvasive excrement detection method for IBD secondary intraepithelial neoplasia

Resumen de: CN122405817A

The invention relates to the field of biological medicine, in particular to noninvasive excrement TMEM109 gene methylation detection of IBD secondary intraepithelial neoplasia. The invention has the significance that a commercial product and a standardized method for noninvasive monitoring of secondary intraepithelial neoplasia of the inflammatory bowel disease (IBD) by adopting a qMSP/MethyLight method based on fecal sample TMEM109 gene methylation do not exist clinically at present, and huge unsatisfied requirements exist in clinical practice. The enteroscopy frequency in the disease management process of IBD patients can be reduced, the life quality is improved, the medical expenditure is reduced, and early intervention of IBD secondary early cancer is facilitated.

CIRCULATING PERIPHERAL BLOOD MONOCYTES AS A PROGNOSTIC MARKER FOR COMPLICATED AND RESISTANT CROHN'S DISEASE

Resumen de: US20260201470A1

0000 Described herein are systems and methods for identifying gene clusters in patients that have Crohn's Disease (CD). Further provided herein are systems and methods for determining or characterizing a Crohn's Disease (CD) subtype status in a subject having CD, selecting a treatment for a subject, or treating a subject.

METHOD TO PREDICT SENSITIVITY TO EMULSIFIER

Resumen de: WO2026150017A1

The present invention relates to a method to predict the sensitivity of a subject to emulsifiers. Here, the inventors explored the use of an in vitro microbiota system and metagenome-based bioinformatic modeling to predict CMC sensitivity of a given microbiota. They found that CMC sensitivity associated with a unique metagenomic signature, supporting the notion that emulsifier sensitivity could be predicted from metagenomic data. They next confirmed that microbiotas predicted to be CMC-sensitive conferred CMC sensitivity when transplanted into colitis-prone IL-10-/- germfree mice. This approach validated the ability of an ex vivo approaches to predict CMC-sensitivity, thereby advancing development of microbiota- based personalized nutrition strategies. Thus, the present invention relates to a method to predict the sensitivity of a subject to emulsifiers comprising determining in a sample obtained from the subject the relative abundance of the microbiota-derived DNA markers listed in the Table A.

COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE

Resumen de: EP4775989A2

The present invention provides methods of diagnosing, treating, and monitoring the progression of inflammatory bowel disease in a subject, including, for example, by monitoring RORγt⁺Th or RORγt⁺Treg cell levels and treating the subject accordingly.

Data management system and method based on inflammatory bowel disease detection

Resumen de: CN122392998A

The invention discloses a data management system and method based on inflammatory bowel disease detection, and relates to the technical field of integrated monitoring of bowel disease detection data, and the method comprises the steps: forming a first detection model based on diagnosis and treatment record data of a medical institution, obtaining self-report data after a patient leaves a hospital, and carrying out the goodness of fit analysis on the self-report data and prediction data, meanwhile, tracking the recurrence data of the inflammatory bowel disease after the patient leaves the hospital; and constructing a second detection model based on the goodness of fit analysis result and inflammatory bowel disease recurrence data after the patient leaves the hospital, grading the medical institutions according to different treatment scores, forming a priority list of each medical institution in the direction of the inflammatory bowel disease, and feeding back the priority list to the administrator port. The objective of the invention is to fundamentally solve the problems of model misalignment and evaluation system disorder caused by deviation of patient off-hospital report data in a current inflammatory bowel disease data acquisition system due to subjective or objective reasons.

Biomarker combination model for evaluating endoscopic activity of pediatric Crohn disease as well as construction method and application of biomarker combination model

Resumen de: CN122385867A

The invention provides a biomarker combination model for evaluating endoscopic activity of pediatric Crohn's disease as well as a construction method and application of the biomarker combination model, and belongs to the technical field of biological medicines. According to the biomarker combination model based on the peripheral blood CD8 + CD69 + T cell proportion combined with the C-reactive protein level, the endoscope activity of a patient suffering from the pediatric Crohn disease can be effectively evaluated through simple peripheral blood detection, and the invasiveness, high cost and potential risks of endoscope detection are avoided; the system is especially suitable for pediatric patients needing frequent monitoring. The model has good diagnosis efficiency, can accurately distinguish patients in an endoscope active period from patients in a remission period, makes up for the defect that clinical activity indexes are inconsistent with endoscope activity, provides a simple, convenient and objective non-invasive evaluation tool for treatment decision, curative effect monitoring and long-term follow-up visit of the pediatric Crohn disease, and has a wide application prospect. Important clinical application values and popularization prospects are realized.

MEASUREMENT OF HYDROGEN SULFIDE DURING BREATH TESTING

Resumen de: WO2018156937A1

Described herein are methods of detecting levels hydrogen sulfide (H2S) to diagnose H2S positive disease or conditions. Examples of H2S positive diseases and conditions include small intestinal bacterial overgrowth, diarrhea, fatigue, bowel urgency and abdominal pain. The H2S level can guide treatments for subjects who have high levels of H2S.

METHODS AND MODELS FOR POST-OPERATIVE RECURRENCE IN CROHN'S DISEASE

Resumen de: US20260193710A1

Provided herein are methods, systems, compositions and kits for modeling post-operative recurrence (POR) or postoperative prophylaxis persistence (POPP) in Crohn's disease patients. The present disclosure provides clinical, serologic, and genetic factors predictive of POR in patients with Crohn's disease. Also provided are clinical, serologic, and genetic factors predictive of POPP in Crohn's disease patients. The clinical, serologic, and genetic factors of the present disclosure are useful for selecting for prognosing, diagnosing, treatment, treating, monitoring a treatment, or optimizing a treatment for a Crohn's disease patient.

USEFUL COMPOUNDS FOR MODULATING INFLAMMATION

Resumen de: US20260193242A1

0000 The present disclosure provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein R to R<3 >and X are defined herein; pharmaceutical compositions; dosage forms comprising the compounds or pharmaceutical compositions, and methods of treating inflammation, decreasing inflammation, decreasing an inflammatory marker, treating inflammatory bowel disease, such as Crohn's disease or ulcerative colitis, or treating sepsis in a subject in need thereof, comprising administering the compounds, pharmaceutical compositions or dosage forms disclosed herein to a subject in need thereof. 0000

PHARMACEUTICAL COMPOSITION FOR TREATING ULCERATIVE COLITIS AND PREPARATION THEREOF

Resumen de: US20260191892A1

0000 The present invention provides a pharmaceutical composition including berberine, militarine, liquiritin, curcumin and atractylenolide III. The pharmaceutical composition is proven to be effective on ulcerative colitis modulating targets including MAOA, MAPK14, AHR, PTGS2, PLA2G1B, and ALOX5. The present invention further provides a method of preparing the pharmaceutical composition including optimization of extraction, determining the quality markers, and optimization of temperature. The present invention further provides a method of treating or alleviating ulcerative colitis.

Image omics and clinical feature identification model based on CT small intestine radiography

Resumen de: CN122348053A

The invention provides a radiomics and clinical feature identification model based on CT small intestine radiography, and relates to the technical field of medical treatment. The identification model comprises data of clinical data, laboratory examination, imaging examination, enteroscopy and pathological examination, imaging omics for extracting intestinal wall and mesenteric fat features based on CT small intestine radiography, and an identification diagnosis model for Crohn's disease and intestinal tuberculosis is constructed through machine learning. By integrating clinical features and radiomics parameters of CT small intestine radiography, a differential diagnosis model of Crohn's disease and intestinal tuberculosis is constructed, and the differential diagnosis model is remarkably superior to a single model. Image omics features reveal essential differences of the two diseases on intestinal wall and mesenteric fat textures. The constructed column diagram provides a convenient visual tool for clinic, and is particularly suitable for accurate diagnosis in areas with high tuberculosis incidence.

Clinical prediction model of anal fistula occurrence probability of Crohn disease patient and design method

Resumen de: CN122337675A

The invention provides a clinical prediction model of anal fistula occurrence probability of a Crohn disease patient and a design method, and belongs to the technical field of clinical medicine. The risk prediction model comprises: an input module receiving patient parameter indexes composed of age during diagnosis, biological agent mode switching and Monte's performance typing during primary definite diagnosis; the processing module is connected with the input module and is used for calculating the evaluation and prediction probability of the anal fistula of the patient suffering from the Crohn disease according to the following formula on the basis of the age during diagnosis, the biological agent mode switching and the Monte performance typing data during primary definite diagnosis; the output module is connected with the processing module and outputs the anal fistula risk probability, obtained by the risk prediction model, of the patient suffering from the Rohn disease. And respectively verifying the prediction model in the training set and the verification set by adopting the area under the curve of the working characteristic curve of the subject and the calibration curve so as to judge the distinction degree and the calibration degree of the prediction model. The risk of anal fistula of a patient suffering from Crohn's disease can be accurately predicted before treatment.

Inflammatory bowel disease assessment method and system

Resumen de: CN122337628A

The invention belongs to the technical field of medical diagnosis assistance, and provides an inflammatory bowel disease assessment method and system.The method includes the steps that biological sample data of a target object is obtained and preprocessed to standardize index data, and the index data is obtained; and calculating multiple scores representing the individual state of the target object based on the preprocessed biological sample data, and constructing a comprehensive evaluation index for quantitatively evaluating the inflammatory bowel disease of the target object based on the scores. According to the scheme provided by the invention, a multi-dimensional comprehensive evaluation index is constructed by integrating multiple index data, so that the pathophysiological essence of the inflammatory bowel disease can be comprehensively and accurately reflected, misdiagnosis or missed diagnosis caused by single-dimensional evaluation is effectively avoided, and the diagnosis accuracy is improved. And a non-invasive, convenient and standardized technical solution is provided for diagnosis, illness monitoring and curative effect evaluation of the inflammatory bowel disease.

Method for analyzing relationship between intestinal microbiota and emotional symptoms of IBS patient

Resumen de: CN122326775A

The invention relates to a method for analyzing a relationship between intestinal microbiota and an emotional symptom of an IBS patient. The method comprises the following steps: determining a causal relationship between the intestinal microbiota and the emotional symptom of the IBS patient; determining that the emotional symptom is caused by reduction of abundance of A. shahii in the intestinal microbiota; determining that the emotional symptom is caused by the reduction of indole produced by metabolism of the intestinal microbiota, and the reduction of indole is caused by the reduction of abundance of A. shahii; determining that the emotional symptom is caused by the decrease of TnAse generated by the intestinal microbiota, the decrease of TnAse is caused by the decrease of abundance of A. shahii, and the decrease of indole is caused by the decrease of TnAse; determining that the emotional symptom is caused by the weakening of AhR signal transduction in the vDG of the IBS patient, and the weakening of AhR signal transduction is caused by the reduction of indole; and determining that the emotional symptoms are caused by the weakening of vDG granular cell viability and the weakening of the vDG granular cell viability is caused by the weakening of AhR signal transduction, thereby obtaining an analysis result that the intestinal microbiota regulates and controls the emotional symptoms through the A. shahii-TnAse-indole-AhR-vDG signal pathway.

Diagnosis and treatment path recommendation method based on IBS multi-dimensional data

Resumen de: CN122337553A

The invention discloses a diagnosis and treatment path recommendation method based on IBS multi-dimensional data, and relates to the technical field of intelligent diagnosis and treatment, and the method comprises the following steps: S1, constructing an IBS treatment scheme library which comprises standardized treatment schemes corresponding to different diagnosis types and different disease severity degrees of IBS, the standardized treatment schemes at least comprise review suggestions, drug recommendation, probiotic recommendation and nursing guidance, and each treatment scheme is associated with a corresponding IBS multi-dimensional data feature threshold. According to the diagnosis and treatment path recommendation method based on the IBS multi-dimensional data, the limitation of single diagnosis data dimension in the prior art is broken through, four core dimensions of symptom data, physical sign data, laboratory examination data and medical history data of a patient are comprehensively integrated, and the symptom data is ensured to be free of omission by combining dual modes of patient autonomous filling and reporting and doctor inquiry; objectivity of physical sign data is guaranteed through professional medical equipment, laboratory inspection data are synchronously obtained from a hospital inspection system, and errors are reduced.

Method of Diagnosing and Treatment of Crohn's Disease and Ulcerative Colitis

Nº publicación: US20260185998A1 02/07/2026

Solicitante:

MCMASTER UNIVERSTIY [CA]
McMaster Universtiy

Resumen de: US20260185998A1

Methods of diagnosing Crohn's disease and ulcerative colitis in subjects is provided based on the determination of metabolites in urine samples, such as serine, hypoxanthine, kynurenine, threonine, indoxylsulfate, phenylacetylglutamine, 5-hydroxy-6-indolyl-O-sulfate, 5-(δ-carboxybutyl) homocysteine, sialic acid, guanidinosuccinic acid (GSA), glutamyl(iso) leucine, trigonelline, cresol sulfate, an anion having m/z: RMT: polarity of 345.1553:0.770: n, aminohippurate: GSA ratiometric biomarker, unknown anion (160.0615:0.830: n): tyrosine ratiometric biomarker and GSA×Tyr: AHA×(an anion having m/z: RMT: polarity of 160.0615:0.830: n) ratiometric biomarker.